CompletedNot Applicable

Diagnostic Role of Serum Testican and Ubiquitin Levels in Patients With Head Trauma

Turkey (Türkiye)89 participantsStarted 2020-10-01

Plain-language summary

We aimed to determine if testican-1 and ubiquitin can serve as early indicators for diagnosing worsening clinical course (presence of intraparenchymal pathology) and mortality in patients with moderate traumatic brain injury.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * being over 18 years old * having a GCS score between 9 and 13 Exclusion Criteria: * under 18 years of age * had missing data * were pregnant * had neurodegenerative disease * had Central Nervous System (CNS) infection * had cerebral palsy * had penetrating head injury (by a cutting or piercing tool such as a firearm, knife, axe) * patients with severe (GCS: 3-8) or mild (GCS: 14-15) TBI

What they're measuring

Comparison of testican-1 and ubiquitin levels in patients with moderate traumatic brain injuries and a control group

Timeframe: The study was conducted with blood samples taken at the time of admission.

Trial details

NCT IDNCT06537713

SponsorKanuni Sultan Suleyman Training and Research Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-03-31

View on ClinicalTrials.gov More Moderate Traumatic Brain Injury trials